Related Experiment Videos
Is angiogenesis inhibition the Holy Grail of cancer therapy?
1Department of Surgical Research, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. boehm_t@a1.tch.harvard.edu
Abstract:
Over the last several decades, oncology research and cancer treatment have concentrated primarily on the cancer cells. Unfortunately, despite the intensive quest to find new and more effective compounds for chemotherapy, the survival rate of patients has not significantly changed. In 1971 Judah Folkman proposed that a solid tumor cannot grow without inducing angiogenesis. Intensive search for molecules blocking the formation of a tumor-nourishing capillary network has identified several promising agents in experimental models. Some of these angiogenesis inhibitors are in clinical trials, but a clear statement about the efficacy cannot be made yet. What are the current trends in angiogenesis research? What areas should we intensively investigate? Can we find the Holy Grail of cancer therapy in the years to come in order to stop the ineffable suffering of millions of cancer patients?
Insights
Cancer research is shifting focus from cancer cells to angiogenesis, the process tumors need to grow. Inhibiting this process shows promise for new cancer therapies.
Area of Science:
- Oncology
- Cancer Biology
- Vascular Biology
Background:
- Traditional cancer treatments focus on targeting cancer cells directly.
- Despite decades of research, chemotherapy has not significantly improved patient survival rates.
- Judah Folkman's 1971 hypothesis highlighted angiogenesis as crucial for solid tumor growth.
Purpose of the Study:
- To review current trends in angiogenesis research for cancer therapy.
- To identify key areas for future investigation in targeting tumor angiogenesis.
- To explore the potential of angiogenesis inhibitors as a "Holy Grail" for cancer treatment.
Main Methods:
- Review of historical and current oncology research trends.
- Analysis of the role of angiogenesis in tumor development.
- Evaluation of experimental and clinical studies on angiogenesis inhibitors.
Main Results:
- Angiogenesis research is emerging as a critical area in oncology.
- Several angiogenesis inhibitors have shown promise in preclinical models.
- Clinical trial data for angiogenesis inhibitors are still pending for definitive efficacy conclusions.
Conclusions:
- Targeting tumor angiogenesis represents a significant paradigm shift in cancer therapy.
- Further research into angiogenesis pathways and inhibitors is essential.
- Angiogenesis inhibition holds potential for a breakthrough in treating various cancers and alleviating patient suffering.